Table 1.

. Retrospective studies reporting on the use of HIPEC for advanced-stage ovarian cancer

First Author	Year	N	Setting	HIPEC Drug	PFS	OS	Serious Complications	Mortality Rate	Outcome
Deraco	2012	56	1st recur -PS and PR	Cisplatin+doxorubicin, cisplatin+mitomycin	10.8mos	25.7mos	26.3%	5.3%
Fagotti	2012	30	1st recur -PS	Oxaliplatin	26mos cases vs 15mos cntr (p=0.004)		34.8%	0%	Recur 67% HIPEC vs 100% control (p=0.001), Death 23% HIPEC vs 62% control (p=0.003)
Bakrin	2013	92	Primary	Cisplatin±doxorubicin, ± mitomycin, oxaliplatin	11.8mos	42mos	31.3%	0.8%	No difference in PS and PR survival
		473	1st recur -PS and PR			45.7mos
Bakrin	2013	36	Primary	Oxaliplatin, mitomycin ± platinum	16.7mos	3yr: 71.5%	20.6%	5.6%
Robella	2014	70	1st recur			28mos	35.7%	7.1%
Cascale-Campos	2014	52	Primary	Paclitaxel	3 yr: 63%				Compared to no HIPEC 3yr PFS: 18% (p<0.01)
Classe	2015	314	1st recur -PS and PR	Cisplatin ± combination	5yr: 14%	5yr: 38%	30.9%	1%	No difference in PS and PR survival
Cascale-Campos	2015	32	1st recur -PS	Paclitaxel	3yr: 45%		21%		Compared to noHIPEC3yr PFS: 23% (p=0.078)
Coccolini	2015	30	Primary	Cisplatin + paclitaxel	12.5mos	32.9mos	35.2%	5.6%
		24	1st recur - PS
Petrillo	2016	70	1st recur -PS	Oxaliplatin, cisplatin	27mos	63mos	8.6%	0%
Munoz-Casares	2016	124	Primary	Paclitaxel, cisplatin	24mos	57mos	13.8%	1.4%
		94	1st recur		19mos	55mos
Di Giorgio	2017	226	Primary		16.6mos	52.4mos	17.4%	2.5%	PS better survival than PR (used 12 mo to define PS)
		285	1st recur -PS and PR

HIPEC, hyperthermic intraperitoneal chemotherapy; PFS, progression-free survival; OS, overall survival; PS, platinum sensitive; PR, platinum resistant